US 12,006,365 B2
Human anti-semaphorin 4D antibody
Ernest S. Smith, W. Henrietta, NY (US); Angelica Cornelison, Pittsford, NY (US); Maria Scrivens, Rochester, NY (US); Mark Paris, Mendon, NY (US); and Maurice Zauderer, Pittsford, NY (US)
Assigned to VACCINEX, INC., Rochester, NY (US)
Filed by VACCINEX, INC., Rochester, NY (US)
Filed on Jul. 19, 2022, as Appl. No. 17/813,375.
Application 17/813,375 is a continuation of application No. 16/611,209, granted, now 11,427,634, previously published as PCT/US2018/031263, filed on May 4, 2018.
Claims priority of provisional application 62/501,981, filed on May 5, 2017.
Prior Publication US 2022/0356249 A1, Nov. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 39/00 (2006.01); C07K 16/00 (2006.01); C07K 16/28 (2006.01); C07K 16/46 (2006.01)
CPC C07K 16/2803 (2013.01) [A61K 2039/505 (2013.01); C07K 2317/33 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 27 Claims
 
1. A composition comprising an antibody or antigen-binding fragment thereof that specifically binds to semaphorin-4D (SEMA4D) comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises complementarity determining regions (HCDRs) HCDR1, HCDR2, and HCDR3 comprising amino acid sequences SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, respectively; and wherein the VL comprises complementarity determining regions (LCDRs) LCDR1, LCDR2, and LCDR3 comprising amino acid sequences SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8, respectively; and
wherein the VH comprises an amino acid sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 1 and/or the VL comprises an amino acid sequence at least 80%, 85%, 90%, 95%, or 100% identical to SEQ ID NO: 5.